Interesting and thought provoking comment Ttppxx.But of course I...

Interesting and thought provoking comment Ttppxx.

But of course I quoted the entire paragraph because I was also bemused by the continuing ChatGpt statement:
"...which may also be integrated into alpha treatment therapies..."

This is also incorrect as I understand CU6's key focus is currently based on Cu67's beta emitting product, which has nothing whatsoever to do with, and at this stage certainly is not "integrated" with any alpha treatment therapy.
Separately, and more on an experimental basis at this stage, CU6 has announced that it is evaluating an alpha emitting Ac225 product.
As per July 15 announcement;
"Clarity will continue to focus on 67Cu-SAR-bisPSMA as its key program in PSMA-expressing prostate cancer because of the proven efficacy and robust safety profile of beta emitters affordsan opportunity to target first line therapy, while 225Ac-bisPSMA has potential to provide benefits to patients in later-stage disease."